Percutaneous Coronary Intervention

The American College of Cardiology and American Heart Association issued updated practice guidelines for the management of patients with acute coronary syndrome.

Since the advent of drug-eluting stents, there has been a debate in the intervention community over how long dual antiplatelet therapy should last after PCI.

CABG plus surgical aortic valve replacement for treatment of coronary disease and aortic stenosis was associated with better 5-year outcomes vs. PCI plus transcatheter aortic valve replacement in Medicare beneficiaries, a speaker reported.

Updates in new antiplatelet therapies, new patient populations for PCI and AI to guide CAD staging were among the top developments in thrombosis and coronary disease from 2024.

In part one of a three-part Healio exclusive series, experts discussed the need for clinical guidance and evidence for the use of AI to improve cardiovascular outcomes.

WASHINGTON — A bioadaptor implant adaptable to vessel physiology was linked to fewer target lesion failure events after 6 months compared with a drug-eluting stent, including in high-risk lesions, researchers reported.

WASHINGTON — Contradicting previous research, in a large trial of patients referred for PCI after acute MI, colchicine did not improve CV outcomes compared with placebo, according to the CLEAR SYNERGY (OASIS-9) trial presented at TCT 2024.

Cardiologists preferred to advise diet and exercise for patients with obesity over currently available obesity medications, but with little personalized tailoring for patients, survey results showed.

The Society for Cardiovascular Angiography and Interventions has released a consensus statement on how catheterization laboratories should manage the technical aspects of PCI for patients with STEMI.

The bioadaptor implant adaptable to vessel physiology was noninferior to a drug-eluting stent for target lesion failure at 1 year, and reduced event rates vs. the DES after 6 months, researchers reported.